Oxyview Reaches Out to Entire COPD Community in the $4 Billion Respiratory Market
Ingen Technologies, Inc. recently announced that Oxyview was published in the March-2009 issue of HomeCare Magazine, and in the Spring-2009 issue of COPD Digest <font> . </font> COPD, chronic obstructive pulmonary disease, was the underlying cause of 718,077 U.S. deaths in 2000-2005, and it was the underlying cause of about 1 in 20 U.S. deaths for 2005 alone. With more than 20 million Americans diagnosed with COPD and another 12 million projected as being undiagnosed, Oxyview has an annual estimated projected revenue of $30M in the USA, and much greater in the global arena with an expected 600M COPD victims worldwide.
Ingen is Granted Patent Rights for China in Estimated $200M Market
Ingen Technologies, Inc. has announced that the Chinese State Intellectual Property for the People's Republic of China is prepared to grant patent rights for Oxyview. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought, according to researchers in Guangdong. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought. According to an estimation by the World Health Organization, COPD ranks first among the burdens of diseases in China and accounts for one million deaths and five million disabilities each year.
$0.0 (07/21/09)
